Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 18/20 | 0.53 |
| ▸ | ATXN2 | Q99700 | 14/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16962872 | 1.00 | ENPP2 (0.53) | ENPP2ATXN2DGAT2 | |
| SCHEMBL17310813 | 1.00 | ENPP2 (0.53) | ENPP2ATXN2DGAT2 | |
| SCHEMBL17310731 | 1.00 | ENPP2 (0.53) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16962874 | 1.00 | ENPP2 (0.53) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16962314 | 0.94 | ENPP2 (0.52) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16962316 | 0.94 | ENPP2 (0.52) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16963462 | 0.94 | ENPP2 (0.52) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16962987 | 0.94 | ENPP2 (0.52) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16962579 | 0.94 | ENPP2 (0.52) | ENPP2ATXN2DGAT2 | |
| SCHEMBL21313980 | 0.94 | ENPP2 (0.52) | ENPP2ATXN2DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | ENPP2 1716/4885ATXN2 669/4885DGAT2 3583/4885 |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | ENPP2 1981/4885ATXN2 791/4885DGAT2 3525/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | ENPP2 1981/4885ATXN2 791/4885DGAT2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.